Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lillian Choi

Gastroenterology Merced, CA Medical Doctor

NPI 1790769818 CMS profile 784653

360 E Yosemite Ave Ste 300, Merced, CA 95340

Open in the dashboard

General payments

$2,534

139 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lillian Choi of Merced, CA is reported in the CMS Open Payments database as having received $2,534 across 139 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $227 7
2024 General $134 6
2023 General $25 1
2022 General $15 1
2021 General $354 19
2020 General $523 38
2019 General $1,255 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lillian Choi
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Lillian Choi were reported at $227. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Lillian Choi Gastroenterology median Middle half National median
2019 $1,255 $417 $126–$1,100 $163
2020 $523 $224 $74–$624 $114
2021 $354 $352 $106–$1,054 $132
2022 $15 $448 $129–$1,270 $149
2023 $25 $533 $150–$1,390 $160
2024 $134 $605 $160–$1,606 $164
2025 $227 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $699 37 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $456 21 payments
  3. Gilead Sciences, Inc. $441 30 payments
  4. Shionogi Inc $186 13 payments
  5. Janssen Biotech, Inc. $134 7 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $106 7 payments
  7. Daiichi Sankyo Inc. $86 5 payments
  8. Intercept Pharmaceuticals, Inc. $86 1 payment
  9. Pfizer Inc. $58 3 payments
  10. Medivators Inc. $48 1 payment
  11. Other $234 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,528 138 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $346 14 payments
  2. Mulpleta $186 13 payments
  3. MAVYRET $181 8 payments
  4. HUMIRA $175 15 payments
  5. CREON $143 9 payments
  6. STELARA $134 7 payments
  7. Epclusa $120 1 payment
  8. INJECTAFER $86 5 payments
  9. OCALIVA $86 1 payment
  10. Vemlidy $82 1 payment
  11. Other $701 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

72

Median for Gastroenterology: 569

Drug cost

$34,283

Median for Gastroenterology: $104,976

Branded share of claims

68.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 11 $33,489
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 19 $286
Omeprazole Generic 23 $257
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 19 $252

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$29,965

Medicare's payments for the services billed

Medicare patients

80

Average age 71

Services billed

230

59 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 36%
Diabetes 34%
Ischemic heart disease 21%
Depression 16%
Osteoporosis 16%
Atrial fibrillation 15%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $42
$42 11 —
STELARA
  • Janssen Biotech, Inc. $31
$31 — —
IBSRELA
  • Ardelyx, Inc. $23
$23 — —
Linzess
  • Ironwood Pharmaceuticals, Inc $21
$21 — —
MAVYRET
  • AbbVie, Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

139 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record